Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych CASC / OSCEPsychopharmacology — SSRIs

Psych CASC / OSCE · Psychopharmacology — SSRIs

Starting an SSRI with black-box counselling (CASC)

CASC-style station: collaborative consent for SSRI start, accurate black-box explanation, sexual side-effect and discontinuation counselling, safety plan, without coercion or false reassurance.

communication
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 19-year-old with first-episode moderate–severe major depression and social anxiety attends with a parent. They fear antidepressants are 'addictive' and have read online that SSRIs 'cause suicide.' The GP suggested sertraline but they want to refuse all medicine.

Station instructions (candidate)

You have 7 minutes. Engage the patient and parent. Validate fears about suicide risk and addiction language online. Explain accurately that SSRIs are not addictive in the substance-use sense but can cause discontinuation symptoms if stopped abruptly, and that a black-box warning means closer early monitoring because a minority of young people experience increased suicidal thoughts after starting — while untreated depression also carries suicide risk.[1][2][5] Offer a collaborative plan: optional sertraline start low, early review, safety plan, sexual side-effect discussion, and psychological therapy pathway. Do not coerce. Do not claim zero risk. Do not dismiss the parent.

Marking domains

Rapport and agenda; accurate black-box explanation without terror or denial; addiction vs discontinuation distinction; sexual side-effect consent; safety planning and early review; shared decision including right to decline; parent involvement with young adult autonomy respected; link to guideline-supported role of SSRIs in moderate–severe depression.[1][3][4][6]

Model communication map

  1. Open: thank them; name goals (feel better, stay safe, keep uni functioning).[3]
  2. Validate media fears: the warning exists because some young people get more suicidal thoughts early — that is why we check soon, not because the tablet is a death sentence.[1][2]
  3. Balance untreated illness: depression itself raises suicide risk; therapy and/or medicine can help moderate–severe illness.[3][6]
  4. Not addiction: you do not get a high or compulsive drug-seeking like opioids; if stopped suddenly you can feel dizzy or 'electric shocks' — we taper later.[5]
  5. Sexual SE: many people get reduced libido or delayed orgasm — we ask and can adjust if it happens.[4]
  6. Plan if starting: sertraline example 25–50 mg oral daily; review within 1–2 weeks; crisis contacts; parent role agreed; CBT/psychology referral.[3]
  7. If declining medicine: honour choice; safety net; therapy-first still valid with close follow-up; door open to revisit.[3]
  8. Close: written plan; next appointment; what to do if worse tonight.[1]

Common fails

  • Saying “black box means you must never take SSRIs under 25.”[1][7]
  • Calling SSRIs addictive like benzodiazepines/opioids.[5]
  • Omitting sexual side-effects entirely.[4]
  • Coercing start without safety plan or early review date.[2]
  • Ignoring the parent’s fear or the patient’s autonomy.[3]

Optional OSCE skill add-on (2 minutes)

Write a one-line prescription teaching dose for sertraline start and state three red-flag symptoms that should trigger same-day contact (worsening suicidal ideation, severe agitation/akathisia, allergic reaction/serotonin toxicity features).[1][3]

References

  1. [1]Hammad TA, Laughren T, Racoosin J Suicidality in pediatric patients treated with antidepressant drugs Arch Gen Psychiatry, 2006.PMID 16520440
  2. [2]Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration BMJ, 2009.PMID 19671933
  3. [3]Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders Aust N Z J Psychiatry, 2021.PMID 33353391
  4. [4]Montejo AL, Llorca G, Izquierdo JA, et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients J Clin Psychiatry, 2001.PMID 11229449
  5. [5]Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research J Clin Psychiatry, 2006.PMID 16683860
  6. [6]Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis Lancet, 2018.PMID 29477251
  7. [7]March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial JAMA, 2004.PMID 15315995